OR Royalties (NYSE:OR – Get Free Report) is expected to release its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect the company to post earnings of $0.31 per share and revenue of $97.9330 million for the quarter. Investors may visit the the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, August 6, 2026 at 10:00 AM ET.
OR Royalties (NYSE:OR – Get Free Report) last announced its quarterly earnings data on Wednesday, May 6th. The basic materials company reported $0.40 earnings per share for the quarter, beating the consensus estimate of $0.34 by $0.06. OR Royalties had a return on equity of 15.10% and a net margin of 78.09%.The business had revenue of $102.83 million during the quarter, compared to analyst estimates of $103.27 million. On average, analysts expect OR Royalties to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.
OR Royalties Price Performance
NYSE:OR opened at $29.44 on Wednesday. The company has a market capitalization of $5.51 billion, a P/E ratio of 21.97 and a beta of 0.74. The business has a fifty day simple moving average of $32.49 and a two-hundred day simple moving average of $37.74. OR Royalties has a 1 year low of $27.40 and a 1 year high of $48.06.
OR Royalties Increases Dividend
Wall Street Analyst Weigh In
Several equities research analysts have commented on the stock. Royal Bank Of Canada dropped their price objective on shares of OR Royalties from $50.00 to $45.00 and set an “outperform” rating on the stock in a report on Thursday, July 9th. Weiss Ratings cut shares of OR Royalties from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Friday. Jefferies Financial Group dropped their price target on shares of OR Royalties from $40.00 to $34.00 and set a “hold” rating on the stock in a research note on Monday, July 6th. Zacks Research downgraded shares of OR Royalties from a “hold” rating to a “strong sell” rating in a report on Monday, July 13th. Finally, Scotiabank reduced their price objective on shares of OR Royalties from $51.00 to $42.00 and set a “sector perform” rating for the company in a research note on Tuesday, July 14th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $40.50.
Read Our Latest Analysis on OR
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of the stock. Elliott Investment Management L.P. increased its position in shares of OR Royalties by 42.7% in the fourth quarter. Elliott Investment Management L.P. now owns 3,111,000 shares of the basic materials company’s stock worth $110,098,000 after purchasing an additional 930,849 shares during the last quarter. XTX Topco Ltd purchased a new position in OR Royalties in the 4th quarter worth approximately $832,000. Yaupon Capital Management LP grew its stake in OR Royalties by 5.6% in the 4th quarter. Yaupon Capital Management LP now owns 205,228 shares of the basic materials company’s stock worth $7,270,000 after buying an additional 10,809 shares in the last quarter. Oxford Asset Management LLP increased its holdings in shares of OR Royalties by 103.6% in the 4th quarter. Oxford Asset Management LLP now owns 26,977 shares of the basic materials company’s stock worth $955,000 after buying an additional 13,724 shares during the last quarter. Finally, Millennium Management LLC bought a new position in shares of OR Royalties in the 4th quarter worth $23,028,000. 68.52% of the stock is currently owned by institutional investors.
OR Royalties Company Profile
OR Royalties PLC (NYSE: OR) is a closed-ended investment company that specializes in acquiring and managing royalty interests in life science and pharmaceutical products. The company provides capital to biotechnology, specialty pharmaceutical and medical device companies in exchange for a share of future sales revenues. By focusing on royalties secured against marketed products, OR Royalties aims to deliver income and growth potential while minimizing the development and commercialization risks typically associated with direct equity stakes.
The company’s core activities include sourcing royalty transactions, structuring bespoke financing solutions and actively monitoring a diversified portfolio of assets.
See Also
- Five stocks we like better than OR Royalties
- These 3 Stocks Have Soared in 2026—Can They Keep Climbing?
- Hasbro’s Earnings Beat Shows Why This Is No Longer Just a Toy Story
- Rambus: Another AI Phoenix Ready to Rise From the Ashes of Correction
- Chips & Clips: Memory Tariffs Rewire Tech Supply Chains
Receive News & Ratings for OR Royalties Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OR Royalties and related companies with MarketBeat.com's FREE daily email newsletter.
